Literature DB >> 24034486

Assessing key model parameters for economic evaluation of pandemic influenza interventions: the data source matters.

Naiyana Praditsitthikorn1, Surachai Kotirum, Adun Mohara, Kuntika Dumrongprat, Román Pérez Velasco, Yot Teerawattananon.   

Abstract

BACKGROUND: In our previous systematic review of economic evaluations of pandemic influenza interventions, five model parameters, namely probability of pandemic, duration of pandemic, severity, attack rate, and intervention efficacy, were not only consistently used in all studies but also considered important by authors.
OBJECTIVES: Because these parameters originated from sources of varying quality ranging from experimental studies to expert opinion, this study aims to analyze the variation in values used according to sources of information across studies.
METHODS: An analysis of estimated values of key parameters for economic modeling was performed against their different data sources, following the standard hierarchy of evidence.
RESULTS: A lack of good-quality evidence to estimate pandemic duration, pandemic probability, and mortality reduction from antiviral treatment results in a large variation of values used in economic evaluations. Although there are variations in quality of evidence used for attack rate, basic reproduction number, and reduction in hospitalizations from antiviral treatment, the estimated values do not vary significantly. The use of higher-quality evidence results in better precision of estimated values compared to lower-quality sources.
CONCLUSION: Hierarchies of evidence are a necessary tool to identify appropriate model parameters to populate economic evaluations and should be included in methodological guidelines. Knowledge gaps in some key parameters should be addressed, because if good-quality evidence is available, future economic evaluations will be more reliable. Some gaps may not be fulfilled by research but consensus among experts to ensure consistency in the use of these assumptions.
© 2013 Blackwell Publishing Ltd.

Keywords:  costs and cost analysis; disease outbreaks; economic evaluation models; human influenza; model parameters; review

Mesh:

Year:  2013        PMID: 24034486      PMCID: PMC5909394          DOI: 10.1111/irv.12091

Source DB:  PubMed          Journal:  Influenza Other Respir Viruses        ISSN: 1750-2640            Impact factor:   4.380


  20 in total

1.  [Impact on the direct medical cost related to the influenza virus during 2009 in children under 5 years compared to the period 2006-2008 in a pediatric hospital].

Authors:  Norberto D Giglio; Vanesa E Castellano; Ricardo W Rüttimann; Gabriela I Vidal; Angela Gentile
Journal:  Arch Argent Pediatr       Date:  2012 Jan-Feb       Impact factor: 0.635

Review 2.  Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997.

Authors:  Nicola Cooper; Douglas Coyle; Keith Abrams; Miranda Mugford; Alexander Sutton
Journal:  J Health Serv Res Policy       Date:  2005-10

3.  Use of tent for screening during H1N1 pandemic: impact on quality and cost of care.

Authors:  Jay Pershad; Teresa M Waters
Journal:  Pediatr Emerg Care       Date:  2012-03       Impact factor: 1.454

4.  Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model.

Authors:  Beate Sander; Azhar Nizam; Louis P Garrison; Maarten J Postma; M Elizabeth Halloran; Ira M Longini
Journal:  Value Health       Date:  2008-07-30       Impact factor: 5.725

5.  [Cost-effectiveness of vaccinating pregnant women against pandemic influenza in Colombia].

Authors:  Luz Angela Chocontá-Piraquive; Nelson Alvis Guzmán; Fernando De la Hoz Restrepo
Journal:  Rev Panam Salud Publica       Date:  2012-06

6.  Simulating school closure policies for cost effective pandemic decision making.

Authors:  Ozgur M Araz; Paul Damien; David A Paltiel; Sean Burke; Bryce van de Geijn; Alison Galvani; Lauren Ancel Meyers
Journal:  BMC Public Health       Date:  2012-06-18       Impact factor: 3.295

7.  Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States.

Authors:  Lisa A Prosser; Tara A Lavelle; Anthony E Fiore; Carolyn B Bridges; Carrie Reed; Seema Jain; Kelly M Dunham; Martin I Meltzer
Journal:  PLoS One       Date:  2011-07-29       Impact factor: 3.240

8.  Health costs from hospitalization with H1N1 infection during the 2009-2010 influenza pandemic compared with non-H1N1 respiratory infections.

Authors:  Paul Zarogoulidis; Dimitrios Glaros; Theodoros Kontakiotis; Marios Froudarakis; Ioannis Kioumis; Ioannis Kouroumichakis; Anastasios Tsiotsios; Anastasios Kallianos; Paschalis Steiropoulos; Konstantinos Porpodis; Evagelia Nena; Despoina Papakosta; Aggeliki Rapti; Theodoros C Constantinidis; Theodora Kerenidi; Maria Panopoulou; Georgia Trakada; Nikolaos Courcoutsakis; Evangelia Fouka; Konstantinos Zarogoulidis; Efstratios Maltezos
Journal:  Int J Gen Med       Date:  2012-03-05

9.  A cost-effectiveness analysis of "test" versus "treat" patients hospitalized with suspected influenza in Hong Kong.

Authors:  Joyce H S You; Eva S K Chan; Maggie Y K Leung; Margaret Ip; Nelson L S Lee
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

10.  Is a Mass Immunization Program for Pandemic (H1N1) 2009 Good Value for Money? Early Evidence from the Canadian Experience.

Authors:  Beate Sander; Chris Bauch; David N Fisman; R Fowler; Jeffrey C Kwong; Allison McGeer; Marija Zivkovic Gojovic; Murray Krahn
Journal:  PLoS Curr       Date:  2009-12-17
View more
  1 in total

1.  Developing a dynamic HIV transmission model for 6 U.S. cities: An evidence synthesis.

Authors:  Emanuel Krebs; Benjamin Enns; Linwei Wang; Xiao Zang; Dimitra Panagiotoglou; Carlos Del Rio; Julia Dombrowski; Daniel J Feaster; Matthew Golden; Reuben Granich; Brandon Marshall; Shruti H Mehta; Lisa Metsch; Bruce R Schackman; Steffanie A Strathdee; Bohdan Nosyk
Journal:  PLoS One       Date:  2019-05-30       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.